NetworkNewsBreaks – Mydecine Innovations Group (
Post# of 160
(Total Views: 170)
Posted On: 01/13/2022 4:27:34 PM
NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of substances in its Special Access Program (“SAP”), creating an opportunity for MYCOF to provide critical resources in helping thousands of healthcare professionals and clinics offer these treatments to those in need. The Health Canada announcement allows practitioners and pharmacists to request and prescribe psilocybin and MDMA for patients who have not experienced success with current treatments. Mydecine’s SASSP is designed so that healthcare practitioners can purchase a package including cGMP psilocybin and MDMA as well as investigative brochures, therapy manuals, protocol training, advisory services, and post-therapy patient support. The program is offered through Mydecine’s wholly owned subsidiary Mindleap Health. “The goal of our Special Access Support and Supply Program is to help physicians who want to prescribe these treatments to their patients but might not have access to the drug product in Canada or experience implementing psychedelic-assisted psychotherapy,” said Mydecine CEO Josh Bartch in the press release. “It’s extremely encouraging to see these much-needed treatments gaining government acceptance, and now we need to enable successful therapy outcomes. Outside of safe drug products, practitioners need access to the resources and the proper training to provide these treatments to their patients. By launching this program, we are providing the resources the thousands of non-psychedelic clinics and hospitals will need in order to safely and effectively integrate these therapies into existing medical practices.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of substances in its Special Access Program (“SAP”), creating an opportunity for MYCOF to provide critical resources in helping thousands of healthcare professionals and clinics offer these treatments to those in need. The Health Canada announcement allows practitioners and pharmacists to request and prescribe psilocybin and MDMA for patients who have not experienced success with current treatments. Mydecine’s SASSP is designed so that healthcare practitioners can purchase a package including cGMP psilocybin and MDMA as well as investigative brochures, therapy manuals, protocol training, advisory services, and post-therapy patient support. The program is offered through Mydecine’s wholly owned subsidiary Mindleap Health. “The goal of our Special Access Support and Supply Program is to help physicians who want to prescribe these treatments to their patients but might not have access to the drug product in Canada or experience implementing psychedelic-assisted psychotherapy,” said Mydecine CEO Josh Bartch in the press release. “It’s extremely encouraging to see these much-needed treatments gaining government acceptance, and now we need to enable successful therapy outcomes. Outside of safe drug products, practitioners need access to the resources and the proper training to provide these treatments to their patients. By launching this program, we are providing the resources the thousands of non-psychedelic clinics and hospitals will need in order to safely and effectively integrate these therapies into existing medical practices.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)